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Inhibition of the Cardiac Na Channel Nav1.5 by Carbon
Monoxide*
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Background: CO poisoning causes cardiac arrhythmias, in part via modulation of the cardiac Na channel, Nav1.5.
Results:CO inhibition of peak recombinant Nav1.5 current occurs via nitric oxide formation and is also dependent on channel
redox state.
Conclusion: CO inhibits peak recombinant Nav1.5 current via a mechanism distinct from activation of the late Na current.
Significance: COmay induce Brugada-like arrhythmias via inhibition of peak Na current.
Sublethal carbonmonoxide (CO) exposure is frequently asso-
ciatedwithmyocardial arrhythmias, and our recent studies have
demonstrated that these may be attributable to modulation of
cardiac Na channels, causing an increase in the late current
and an inhibition of the peak current. Using a recombinant
expression system, we demonstrate that CO inhibits peak
human Nav1.5 current amplitude without activation of the late
Na current observed in native tissue. Inhibition was associated
with a hyperpolarizing shift in the steady-state inactivation
properties of the channels and was unaffected by modification
of channel gating induced by anemone toxin (rATX-II). System-
atic pharmacological assessment indicated that no recognized
CO-sensitive intracellular signaling pathways appeared to
mediate CO inhibition of Nav1.5. Inhibition was, however,
markedly suppressed by inhibition of NO formation, but NO
donors didnotmimic or occlude channel inhibitionbyCO, indi-
cating that NO alone did not account for the actions of CO.
Exposure of cells to DTT immediately before CO exposure also
dramatically reduced the magnitude of current inhibition. Sim-
ilarly, L-cysteine andN-ethylmaleimide significantly attenuated
the inhibition caused byCO. In the presence ofDTTand theNO
inhibitor N-nitro-L-arginine methyl ester hydrochloride, the
ability of CO to inhibit Nav1.5 was almost fully prevented. Our
data indicate that inhibition of peak Na current (which can
lead to Brugada syndrome-like arrhythmias) occurs via a mech-
anism distinct from induction of the late current, requires NO
formation, and is dependent on channel redox state.
Carbon monoxide (CO) is receiving much interest as an
endogenous cell signaling molecule, and its role as a physiolog-
ical regulator and potential therapeutic agent has been the sub-
ject of several recent reviews (e.g. Refs. 1–4). In the heart, both
atrial and ventricular myocytes express the CO-generating
enzymes HO-1 and HO-2 (HO-1 is induced by stress factors
such as myocardial infarction (5)), and evidence suggests that
some effects of endogenous CO may protect the myocardium,
for example by limiting cellular damage caused by ischemia/
reperfusion injury in the heart (6). Indeed, HO-1 knock-out
increases (7) and HO-1 overexpression decreases (8) cardiac
damage following ischemia/reperfusion injury. We have previ-
ously proposed that the cardioprotective effects of CO may in
part arise due to its ability to reduce Ca2 influx into myocytes
via L-type Ca2 channels (9).
Despite these advances in our understanding of the biology
of CO, it remains an established environmental toxin, account-
ing for 50% of all fatal poisonings (10–12). The markedly
different effects of exogenous and endogenous CO may reflect
differences in the average tissue concentration or more subtle
localized effects, present only when CO is produced intracellu-
larly. Exogenous CO sources include motor exhaust fumes, gas
appliances, wood burners, propane engines, and tobacco
smoke. The myocardium is particularly susceptible to CO poi-
soning; chronic exposure to CO can induce myocardial injury
and fibrosis (13–15), whereas acute exposure is associated with
arrhythmias, which can in turn lead to sudden death (13, 16).
CO also increases the likelihood of arrhythmias in patients with
existing cardiac conditions (17, 18). Arrhythmic effects do not
correlate with carboxyhemoglobin levels (13, 19), suggesting
that tissue hypoxia does not account for its cardiotoxicity.
Instead, electrocardiogram alterations in CO-exposed individ-
uals indicate specific, pro-arrhythmic electrophysiological
modifications (13, 20–22) which are mimicked in conscious
rats (23). We recently proposed that CO-induced prolongation
of the QT interval was attributable to induction of the late Na
current, causing delay of repolarization. This arose due to CO-
induced nitrosylation of the Na channel protein Nav1.5 fol-
lowing activation of endogenous NO formation (24). In that
study, we also noted a reduction of the peak Na current, an
effect that is also potentially arrhythmic because it is a feature of
many forms of Brugada syndrome (25). To explore the mecha-
nisms accounting for this important additional effect of CO on
cardiac Na channels, we have examined the influence of CO
on recombinant human Nav1.5. Our results indicate that CO
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reduces the peak Na current via a mechanism that is distinct
from its action to induce the late Na current.
EXPERIMENTAL PROCEDURES
Cell Culture—HEK293 cells stably transfected with the full-
length human cardiac sodium channel (SCN5A clone hH1,
GenBankTM accession no. M77235) were kindly provided by
J. C. Makielski (University of Wisconsin) (26). Cells were
cultured in growth medium comprising minimal essential
medium with Earle’s salts and L-glutamine, supplemented with
10% (v/v) fetal calf serum (Biosera, Ringmer, UK), 1% (v/v) non-
essential amino acids, 1% (v/v) sodium pyruvate (Sigma), 50
g/ml gentamicin, 100 units/ml penicillin G, 100 g/ml strep-
tomycin, and 0.25 g/ml amphotericin in a humidified atmo-
sphere of air/CO2 (19:1) at 37 °C. Selection pressure was main-
tained with G-418 (400 g/ml). All culture reagents were
purchased from Invitrogen unless otherwise stated.
nNOS Transfection—cDNA encoding rat neuronal nitric
oxide synthase (rat nNOS;2NM_052799) was originally excised
from pcDNA3/rat nNOS (a kind gift from J. C. Makielski, Uni-
versity ofWisconsin) and subcloned (via 5-EcoRI and 3-XhoI)
into pcDNA3.1(NeoR). To enable visualization of successfully
transfected cells, rat nNOS (5-NheI and 3-XhoI) was then
subsequently subcloned into pIRES-EGFP-puro (Addgene
plasmid no. 45567; kindly deposited by Prof. Michael McVoy,
Virginia Commonwealth University School of Medicine, Rich-
mond, VA). HEK293 cells stably expressing Nav1.5 were tran-
siently transfected with rat nNOS as follows: 1  106 cells were
resuspended in 100 l of NucleofectorR solution V (Lonza) at
room temperature, 2 g of DNA (pIRES-EGFP-puro/rat
nNOS) were added, and the suspension was subjected to
nucleofectorR programQ-01 as per themanufacturer’s instruc-
tions (Lonza). The nNOS-transfected (GFP-positive) cells were
sorted into sterile PBS containing 10% fetal calf serum on a
Becton Dickenson FACSAria IIu using FACSDiva software
(version 6.0). The suspension was then diluted in culture
medium and transferred to coverslips at the appropriate den-
sity for electrophysiology or immunofluorescence analysis.
Cells were used, or fixed, 24–48 h following transfection.
Immunofluorescence—Coverslips with transfected or untrans-
fected cells werewashed (2) inDulbecco’s phosphate buffered
saline (DPBS, Sigma-Aldrich) and then fixed with 4% parafor-
maldehyde in DPBS (20 min at room temperature). Coverslips
were then washed (3 for 5 min) in DPBS. Cells were perme-
abilized by incubation with 0.05% Triton X-100 in DPBS con-
taining 10% normal goat serum (for 20 min at room tempera-
ture). Afterwashing, cells were incubated overnight at 4 °Cwith
anti-nNOS (clone 3G6B10, Invitrogen, 1:250) inDPBS contain-
ing 1% normal goat serum. Cells were washed (3 for 5 min)
and then incubated with Alexa FluorR 488 or 633 conjugated
donkey anti-mouse (Invitrogen, 1:1000) inDPBS containing 1%
normal goat serum. Coverslips were washed (3 for 5 min),
mounted using VectashieldR containing DAPI (Vector Labora-
tories, Burlingame, CA), and sealedwith nail polish. Slides were
examined on an LSM510 confocal microscope running Zen
software (Carl Zeiss).
Electrophysiology—Whole-cell patch clamp recordings were
used to study macroscopic Na currents at room temperature
(23 2 °C). Patch pipettes (2 to 5megohms)were filledwith the
following: 120mMCsF, 20mMCsCl, 5mMEGTA, bufferedwith
5mMHEPES; pHwas adjusted to 7.2withCsOH.Cells attached
to coverslips were placed in a perfused (2–4 ml/min) chamber
using extracellular solution containing the following: 10 mM
NaCl, 130 mM choline chloride, 4 mM KCl, 1.8 mM CaCl2, 0.75
mM MgCl, 10 mM glucose, buffered with 5 mM HEPES. Na
levels were reduced to 10 mM to reduce the current amplitudes
to levels that allowed accurate voltage clamp. Extracellular pH
was adjusted to 7.4 with NaOH and osmolarity of both solu-
tions was 300 mOsm. After gigaohm seal formation and estab-
lishment of whole-cell voltage clamp, whole-cell currents were
recorded, digitized, and stored with an Axopatch 200B ampli-
fier, Digidata 1322A, and pCLAMP 9 (Molecular Devices,
Union City, CA). Currents were sampled at 50 kHz and low
pass-filtered at 20 kHz. Series resistance was compensated by
70–90%.
PeakNa currents were recorded by stepping from a holding
potential of 100 to 30 mV for between 40 ms and 400 ms.
Start-to-start time between sweeps was 4 or 10s. I-V relation-
ships were measured by stepping from a holding potential of
100mV to voltages between120mVand40mV in 10-mV
increments for 50-ms each (1 Hz). Time series studies
employed repeated 50-ms step depolarizations ranging from
100mV to30mV (0.1Hz). Steady-state inactivation ofNa
currents was measured by applying pre-pulses ranging from
120 to 50 mV in 10-mV increments for 5 s prior to the test
potential (30 mV for 100 ms). Currents were measured at
their peak and at 100 ms (for late current) following leak sub-
traction by the P/4 method. Analysis was performed using
Clampfit 9 (Molecular Devices, Sunnyvale, CA), and subse-
quent curve-fitting and statistical analysis was undertaken
using GraphPad Prism (version 4, GraphPad Software, La Jolla,
CA).
Confocal DAF-2 Imaging—Cells were incubated for 60min at
37 °C in extracellular solution composed of the following: 140
mM NaCl, 5 mM KCl, 1.5 mM CaCl2, 2 mM MgCl2, 10 mM
HEPES, 11 mM glucose, pH 7.4) containing DAF-2 diacetate (5
M), a cell membrane-permeable NO-sensitive fluorescent dye
(27). Cells were then gently washed twice with extracellular
solution and left for at least 15 min in an incubator to allow the
hydrolysis of DAF-2 diacetate into the free NO-sensitive free
acid form (DAF-2). Cells were placed on a Zeiss (Oberkochen,
Germany) laser scanning confocalmicroscope (LSM510) fitted
with 40 oil immersion lens (Zeiss Plan Neofluar, refractive
index of 1.3) and continuously perfused at 0.5 ml/min. DAF-2
loaded cells were excited with the 488-nm line of a 20-mW
diode laser (attenuated by 90%), and emitted fluorescence
was measured at 515 nm. x-y images were obtained from
isolated cells at 1-min intervals to minimize photobleaching
using Zeiss AIM software. Fluorescence intensity was analyzed
2 The abbreviations used are: nNOS, neuronal nitric oxide synthase; DPBS,
Dulbecco’s phosphate buffered saline; MnTMPyP, Mn(III)terakis(1-methyl-
4-pyridyl) porphyrin tetratosylate hydroxide; L-NAME, N-nitro-L-arginine
methyl ester hydrochloride; eGFP, enhanced GFP; ROS, reactive oxygen
species.
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from isolated cells using ImageJ software. Identical settings
were used for each test condition.
Drugs and Solutions—The NO donor (S)-nitroso-N-acetyl-
penicillamine and SB203580 were purchased from Ascent Scien-
tific (AbCam Chemicals, Cambridge, UK). SIN-1 hydrochloride,
Mn(III)terakis(1-methyl-4-pyridyl) porphyrin tetratosylate hy-
droxide (MnTMPyP), and the NO donor S-nitrosoglutathione
were purchased from Calbiochem (Merck Chemicals, Notting-
ham, UK). MitoQ was a gift from Dr. M. Murphy (Cambridge,
UK). Allopurinol, antimycin A, L-ascorbic acid, choline chloride,
DTT, diphenyleneiodonium chloride, 2,2-dithiobis(5-nitropyri-
dine),N-ethylmaleimide, the calcium-andcalmodulin-dependent
protein kinase II (CaMKII) inhibitor KN-93, reduced glutathione,
N-nitro-L-arginine methyl ester hydrochloride (L-NAME), rote-
none, stigmatellin, and superoxide dismutase were purchased
fromSigma-Aldrich.Ebselenwaspurchased fromCaymanChem-
ical (Ann Arbor, MI), and DAF-2 diacetate was purchased from
Invitrogen.Anemone toxinATX-IIwaspurchased fromAlomone
Labs (Jerusalem, Israel). ThePKG inhibitorRp-8-Br-PET-cGMPS
and PKG activator Sp-8-Br-PET-cGMPS were purchased from
BIOLOG Life Science Institute (Bremen, Germany). DTT was
added to the extracellular solution as a reducing agent, andN-eth-
ylmaleimidewasaddedto the intracellular solutionasanalkylating
agent. Where necessary, appropriate precautionary measures
were taken throughout the experimental procedures to avoid deg-
radation of light-sensitive compounds (ascorbic acid, trolox
(Sigma), SIN-1, andMnTMPyP), aswell as to avoid extensivepho-
tobleaching of fluorescent dye. Solution pH was measured before
the start of each experiment because fluorescence of DAF deriva-
tives is highly pH-dependent (28).
Pooled data are presented asmean S.E. Statistical compar-
isons were effected by using Student’s t test and analysis of
variance (where appropriate), with a value of p 	 0.05 consid-
ered significant.
RESULTS
CO Inhibits the Peak Recombinant Nav1.5 Current—As illus-
trated in Fig. 1A, the CO donor CORM-2 caused marked inhi-
bition of the peak Na current recorded in Nav1.5-transfected
cells. Effects were slow to reverse, with only 34.1  5.0% recov-
ery seen after 3-min washout (n 
 10 cells). Strikingly, poten-
tiation of the late current was not apparent (Fig. 1A; detailed
further in Fig. 2). Current inhibition was observed at all activat-
ing test potentials (Fig. 1B), and there was no significant effect
on the voltage dependence of activation (Fig. 1B, inset), with an
IC50 of 1.38 M CORM-2 (Fig. 1C). The CORM-2 solvent,
dimethyl sulfoxide (0.1%) was without significant effect onNa
currents, as was the inactive compound, iCORM (Fig. 1, B and
D). CO dissolved directly into solution as described previously
(24) to a concentration of 87M, was as effective as CORM-2 in
FIGURE 1. CO inhibits recombinant human Nav1.5 channels expressed in HEK293 cells. A, shown are families of currents evoked by step depolarizations
applied from a holding potential of 100 mV to between 70 mV and 40 mV before (control) during (CORM-2) and after a 3-min washout of the CO donor
CORM-2 (3 M). Shown below is a time series plot in which each open plotted point is the measured peak amplitude of current evoked by successive step
depolarizations from 100 mV to 30 mV. For the period indicated by the horizontal bar, the cell was exposed to 3 M CORM-2. The solid symbols show the
amplitude of the late current measured in the same cell. Gaps in the time series represent brief periods when current voltage relationships were recorded. B,
mean  S.E. (error bars) current density versus voltage plots determined in control cells (●; n 
 7), cells exposed to 3 M CORM-2 (E; n 
 7), and cells exposed
to 3 M iCORM (; n 
 7). Effects of CORM were statistically significant (p 	 0.02 to p 	 0.0001) over the voltage range 40 to 40 mV. Inset plots show
normalized current activation curves under control conditions (●; n 
 7) and in the presence of 3 M CORM-2 (E; n 
 7). C, concentration response relationship
indicating the potency of CORM-2 to inhibit Nav1.5 currents. Each point plotted is the mean  S.E. (error bars) inhibition of current determined from seven cells
in each case. The fitted curve revealed an IC50 value of 1.38 M. D, bar graph showing mean  S.E. (error bars) (n 
 9 cells in each case) inhibition caused by
solvent (dimethyl sulfoxide (DMSO); 0.1%), iCORM, CORM-2, and CO dissolved directly into solution. ***, p 	 0.0001 versus control. E, steady-state inactivation
curves determined in four cells before and during exposure to 3 M CORM-2. Each point represents mean  S.E. (error bars), and curves were fitted by
Boltzmann equations. Effects of CORM were statistically significant (p 	 0.01, p 	 0.001) over the voltage range of 100 to 80 mV.
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inhibiting currents (Fig. 1D). Associated with the inhibition of
currents by CORM-2 (3 M) was a hyperpolarizing shift of the
steady state inactivation profile of the current, from a V0.5 of
76.0 2.2mV to89.5 0.81mV (Fig. 1E, n
 4; p	 0.001).
The lack of effect of CO on the late Na current is in striking
contrast to its induction by CO in native tissue (24), suggesting
that the inhibition of the peak Na current occurs via a mech-
anism distinct from late Na current induction. It is conceiv-
able that heterologous expression of the Nav1.5  subunit, in
the absence of auxiliary native proteins, may be unable to gen-
erate a late current. To investigate this, we examined the
response of the recombinant Nav1.5 to anemone toxin (ATX-
II), which can induce the late current in native tissue (29). As
shown in Fig. 2, A–C, bath application of 100 nM rATX-II
caused an induction of the late (persistent) Na current, with-
out affecting the amplitude of the peak current. Effects of the
toxin were essentially irreversible (data not shown) as reported
previously (30). However, subsequent exposure to 3 M
CORM-2 significantly reduced both peak and persistent Na
current amplitude (Fig. 2, A–C), suggesting it inhibits Nav1.5
regardless of the gating alterations caused by rATX-II.
Probing the Mechanism of CO Inhibition of Nav1.5—CO
exerts a range of effects in different tissues via numerous
diverse signaling pathways (1–4). We systematically explored
the possible involvement of these pathways using a variety of
pharmacological interventions, and results are summarized in
Fig. 3.Mitochondria are amajor intracellular source of ROS via
electron “leak” from the electron transport chain (31), and CO
appears to increase ROS production by interacting with cyto-
chrome c oxidase (9, 32–34). For these reasons, and because
ROS levels have been reported to modulate cardiac Na chan-
nel activity (35), we examined the effects of CO in the presence
of known electron transport chain inhibitors. As shown in Fig.
3A, an inhibitor of complex I (rotenone, 2M), two inhibitors of
complex III (stigmatellin (1 M, 30 min of preincubation) and
antimycin A (3 M)), and the combined presence of rotenone
and stigmatellin were unable to modulate the response to CO.
Similarly, the ability of CO to inhibit the peak Na current was
unaffected by allopurinol (1 M, 30 min of preincubation) and
diphenylene iodonium (3 M), discounting the involvement of
ROS derived from xanthine oxidase or NADPH oxidase (Fig.
3B).
We then tested a range of general antioxidants: trolox (400
M), ascorbic acid (500 M), MnTMPyP (100 M), ebselen (1
M, 30 min of preincubation), reduced glutathione (3 mM), and
themitochondria-targeted antioxidant, mitoQ (250 nM, 30min
of preincubation). None of these were effective in altering the
ability of CORM-2 to inhibit currents (Fig. 3C).
CO has been shown to activate the cGMP/PKG pathway to
exert some of its effects (36). We therefore examined its ability
to inhibit Nav1.5 currents in the presence of the soluble guany-
late cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-
one (ODQ; 30 M, 1 h of preincubation), and a membrane-
permeant cGMP activator (Sp-8-Br-cGMPS; 0.5 M, 1 h of
preincubation) and inhibitor Rp-8-Br-PET-cGMPS (0.5M, 1 h
of preincubation). Each compound was ineffective in altering
the ability of CORM-2 to inhibit Nav1.5 (Fig. 3D). Similarly,
inhibition of Nav1.5 currents by CORM-2 was unaltered in the
presence of the CaMK II inhibitor KN-93 (1 M) or the p38
MAPK inhibitor SB-203580 (10 M, 1 h of preincubation).
These experiments suggest that these known CO-sensitive tar-
gets are not involved in the inhibition of Nav1.5 (Fig. 3E).
CO Inhibition of Nav1.5 Requires NO Formation—We
extended the investigation to examine a possible involvement
of NO because CO is an established activator of NO produc-
tion, possibly by activating NOS (2, 37). In the presence of
L-NAME, which prevents NO formation, the ability of CO to
inhibit Nav1.5 was significantly reduced, although not abol-
ished (Fig. 4, A and B). This finding prompted us to investigate
whether CO can stimulate NO formation, as is the case in car-
FIGURE 2. CO inhibits the ATX-II induced late Nav1.5 current. A, shown are
currents evoked in a Nav1.5-expressing HEK293 cell under control conditions,
during exposure to 50 nM rATXII, and during exposure to 3 M CORM-2 fol-
lowing rATXII exposure, as indicated. Currents were evoked by step depolar-
izations from 100 to 30 mV. B, shown is a time series plot in which each
open plotted point is the peak amplitude of current evoked by successive
step depolarizations from 100 to 30 mV (measured 200 ms into pulse
duration). For the periods indicated by the horizontal bar, the cell was
exposed to 50 nM rATXII and then to 3 M CORM-2. The solid symbols show the
amplitude of the late current measured in the same cell. C, bar graph plotting
mean  S.E. (n 
 5 cells) peak (open bars) and late (solid bars) current ampli-
tudes under control conditions and in the presence of 50 nM rATXII and then
3 M CORM-2, as indicated. **, p 	 0.01.
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diac myocytes (24). To this end, we loaded cells with the NO-
sensitive fluoroprobe DAF-2 and found that exposure to
CORM-2 produced a time-dependent increase in the produc-
tion of NO, which was prevented by L-NAME (Fig. 4B). Thus,
CO inhibition of Nav1.5 is in part dependent on its ability to
induce NO formation. However, despite the dependence of the
effects of CO on NO formation, application of NO donors was
not sufficient tomimic the actions of CO. As exemplified in Fig.
5, A and B, application of (S)-nitroso-N-acetylpenicillamine
(200 M; Fig. 5A) or SIN-1 (100 M, applied together with
superoxide dismutase (50 units/ml) to prevent peroxynitrite
formation; Fig. 5B) only exertedminimal effects on peakNav1.5
current amplitude, and their presence did not significantly alter
the ability of CO to inhibit currents (Fig. 5C).
Ueda et al. (38) have demonstrated that in cardiac myocytes
nativeNa channels formpart of amultimeric protein complex
that includes the neuronal form of nitric oxide synthase, nNOS.
Furthermore, NO derived from nNOS increases the late Na
current in HEK293 cells co-expressing Nav1.5  (but not aux-
iliary ) subunits and nNOS (38). To investigate a possible
involvement of nNOS in mediating the effects of CO on
Nav1.5-mediated currents in our HEK293 cells, we co-ex-
pressed nNOS using an eGFP-coexpressing plasmid. As shown
in Fig. 6A (left), nNOS was not detected in untransfected
HEK293 cells visually by immunocytochemistry. However, all
transiently transfected cells, following FACS analysis, consis-
tently expressed nNOS (and eGFP; data not shown). This was
consistently observed in each of four transfections (e.g. Fig. 6A,
right).
As described in Fig. 1, no late current was induced in non-
transfected cells (Fig. 6B, upper traces, Fig. 6C). By contrast, in
all six cells studied following transfection with nNOS, exposure
to CO (3 M) inhibited peak Na current by 60.4 2.4% (com-
parable with the effects seen in untransfected cells; Fig. 1) but
also caused a striking increase in the late current amplitude
(Fig. 6B, left, lower traces, and accompanying time series, Fig.
6B, right). Mean data are shown in Fig. 6C. These data are con-
sistent with the idea that CO can induce the late Na current in
FIGURE 4. CO inhibition of Nav1.5 involves NO formation. A, shown is a
time series plot in which each plotted point is the peak amplitude of current
evoked by successive step depolarizations from 100 to 30 mV. For the
periods indicated by the horizontal bars, the cell was exposed to 1 mM L-NAME
and then to 3 M CORM-2. Inset, bar graph showing the mean  S.E. effects of
3 M CORM-2 alone (n 
 10), or following pretreatment with L-NAME (n 
 10).
***, p 	 0.0001. B, DAF-2 fluorescence measured in HEK293 cells overexpress-
ing Nav1.5. At the point indicated by the arrow, cells were exposed to 3 M
CORM-2. Mean  S.E. fluorescence (plotted as arbitrary units, AU) is shown for
naive cells (solid circles) or cells pretreated with 1 mM L-NAME (open circles; n 

5 in each case). Fluorescence was statistically significantly different between
the two groups at t 
 9 min and later (p 	 0.05 to p 	 0.001).
FIGURE 3. CO inhibits Nav1.5 without involvement of numerous known signaling pathways. Bar graphs show the effects of various agents that interfere
with the ability of CO (applied as CORM-2, 3 M) to reduce the peak Na current amplitude. In each case, mean effects of CORM-2 were determined from the
number of cells (indicated in parentheses). Dashed lines indicate the mean effects of CORM-2 applied alone (i.e. in the absence of other agents; 71.1  0.48%
inhibition, n 
 15)). Agents investigated were designed to probe the involvement of mitochondria. A, 2 M rotenone (Rot.), 1 M stigmatellin (stigm.; 30 min
preincubation), and 3 M antimycin A. B, xanthine oxidase and NADPH oxidase (1 M allopurinol (30-min preincubation), and 3 M diphenyleneiodonium
chloride (DPI)); C, antioxidants (400 M trolox; 500 M ascorbic acid; 100 M MnTMPyP, and 1 M ebselen (30-min pre-incubation), 3 mM glutathione (GSH), and
250 nM mitoQ); D, cGMP/PKG pathway (30 M 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 0.5 M Sp-8-Br-cGMPS, and 0.5 M Rp-8-Br-PET-cGMPS (1-h
preincubation for these three drugs)); E, involvement of other kinases (1 M KN-93, and 10 M SB-203580 (1-h preincubation for both drugs)).
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HEK293 cells only when they co-express nNOS but that nNOS
expression is not required for peak current inhibition. Thus,
they further support the notion that CO inhibition of the peak
Na current is mechanistically distinct from its ability to mod-
ulate the late Na current and requires NO from a distinct
source.
To investigate possible effects on inactivation kinetics, we
fitted the decay phase of nNOS-transfected cells with a double
exponential function before and during exposure to CO. The
fast time constant was slightly but significantly (p 	 0.05)
slowed from1.47 0.12ms to 1.99 0.17ms in the presence of
3 M CORM-2 (n 
 6), whereas the slow time constant was
unaffected (8.61  1.37 ms versus 9.39  1.75 ms).
Nav1.5 Redox Status Influences Sensitivity to COModulation—
Despite the lack of effect of antioxidants to interfere with the
ability of CO to modulate Nav1.5 (Fig. 3), the channel is known
to undergo regulation bymore stringent reducing andoxidizing
agents (39–41), suggesting reactive cysteine residues can reg-
ulate channel function. To examine whether they may influ-
ence channel sensitivity to CO, we first pretreated cells with
such agents and then examined the subsequent response to CO
exposure. As illustrated in Fig. 7A, application of 1 mM DTT
FIGURE 5. NO donors do not mimic CO. A, shown is a time series plot show-
ing the measured peak current amplitude evoked by successive step depo-
larizations from 100 to 30 mV. For the periods indicated by the horizontal
bars, the cell was exposed to 200 M (S)-nitroso-N-acetylpenicillamine and to
3 M CORM-2, as indicated. B, as in A, except that the cell was exposed to 100
M SIN-1 plus superoxide dismutase (SOD; 50 units/ml) rather than (S)-nitro-
so-N-acetylpenicillamine (SNAP). C, bar graph showing mean  S.E. inhibition
of peak Na current (measured as in A and B) caused by 3 M CORM-2 applied
alone (solid bar) or together with the NO donors as used in A and B, and the
effects of the donors alone (n 
 5 cells in each case). ***, p 	 0.0001.
FIGURE 6. Co-expression of nNOS permits CO-induction of the late Na
current. A, immunofluorescent (left) and bright field (BF; center) images of
Nav1.5-expressing HEK293 cells without co-expression of nNOS. Right image
shows immunofluorescence staining for nNOS in cells transiently transfected
with nNOS and eGFP on the pIRES-EGFP-puro plasmid. Scale bars represent 10
M in each case. B, left, shown are currents evoked in a non-transfected cell
(upper traces) and a nNOS-transfected cell (lower traces) before and during
exposure to 3 M CORM-2, as indicated. Currents evoked in each case by step
depolarizations from 100 to 30 mV. Right, shown is a time series plot
showing the measured peak (open symbols) and late (solid symbols) current
amplitudes evoked by successive step depolarizations from 100 to 30 mV.
For the period indicated by the horizontal bar, the cell was exposed to 3 M
CORM-2, as indicated. The cell underwent transfection with nNOS and dem-
onstrates the late current enhancement by CO exposure only seen in these
transfected cells. C, bar graph showing mean  S.E. effects of 3 M CORM-2 on
peak Na current (open bars) and late current (solid bars) caused by applied to
untransfected cells (n 
 5) and nNOS-transfected cells (n 
 6). **, p 	 0.01; ***,
p 	 0.0001.
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(which alone had no significant effect on currents), dramati-
cally reduced the subsequent ability of CORM-2 to inhibit peak
Na currents (quantified in Fig. 7D). Similarly, intracellular
dialysis with the cysteine alkylating agent N-ethylmaleimide
(300M; which itself reduced currents by 8.0 1.7%,n
 5) also
significantly reduced the sensitivity to CORM-2 (Fig. 7, B and
D), as did bath application of L-cysteine (Fig. 7, C and D). Fol-
lowing exposure to both L-NAME and DTT, CORM-2 was
almost completely without effect on Nav1.5 (Fig. 7, E and F).
Thus, our results indicate thatCO inhibition ofNav1.5 is in part
dependent on NO formation and is also dependent on the
redox status of available channel cysteine residues.
DISCUSSION
CO is being championed as a novel therapeutic approach in
the treatment of numerous disorders, including cardiovascular
disease, cancer, inflammation, and also to improve rejection
rates following organ transplantation (42). Furthermore, clini-
cal trials are currently determining its safety and usefulness in
treating a variety of disorders (for more details, search clinical-
trials.gov for “carbon monoxide”) in humans. Despite these
positive prospects, however, CO remains the most common
form of death by poisoning (10, 12). The heart and brain (par-
ticularly in the aging population) are most susceptible to CO-
induced damage (13, 43–45), and symptoms are difficult to
diagnose (46). Experimentally, both positive and negative
effects of CO can be demonstrated. Thus, CO can reduce neu-
ronal damage arising from focal ischemia (47) yet can be detri-
mental through disruption of neuronal Ca2 homeostasis (48).
In the heart, endogenous CO arising from elevated HO-1
expression limits the cellular damage caused by ischemia/
reperfusion injury in mice (6–8), and similar protective results
have been recently reported using theCOdonor, CORM-3 (24).
By contrast, we have recently demonstrated that exogenousCO
(applied directly or via CO donors CORM-2 or CORM-3) can
have proarrhythmic actions at similar concentrations (24).
These findings suggest that there may be a narrow therapeutic
window for CO, at least as a treatment for themyocardium. It is
imperative, therefore, that a full understanding of the molecu-
lar and cellular effects of CO is established before its usefulness
as a therapeutic agent can be exploited.
We demonstrated recently that CO augmented the late Na
current via increased NO production and subsequent nitrosy-
lation of Nav1.5 channel protein (24). This effect led to early
afterdepolarization-like Ca2 transients in singlemyocytes and
proarrhythmic effects in vivo that could precipitate ventricular
fibrillation and death in the presence of isoprenaline (24).
Although it was also noted, no exploration of the mechanism
underlying the additional effect of CO to inhibit peak Na cur-
rents was provided. We did, however, report a hyperpolarizing
shift in the steady-state inactivation curve for the native chan-
nel (24), as shown in Fig. 1E for the recombinant channel. Note,
however, that the standard holding potential for most experi-
FIGURE 7. Cysteine-modulating agents influence Nav1.5 inhibition by CO. A, shown is a time series plot showing the measured peak current amplitude
evoked by successive step depolarizations from 100 to 30 mV. For the periods indicated by the horizontal bars, the cell was exposed to 1 mM DTT and then
to 3 M CORM-2, as indicated. B, as described in A, except that the cell was dialyzed with 300 M N-ethylmaleimide (NEM) rather than exposed to DTT. C, as
described in A except that the cell was exposed to 100 M L-cysteine (L-Cys) rather than DTT. D, bar graph showing mean  S.E. inhibition of peak Na current
(measured as in A–C) caused by 3 M CORM-2 applied alone (solid bar) or together with the cysteine modifying agents used in A–C, and the effects of the donors
alone (n 
 10 for DTT, n 
 9 for N-ethylmaleimide, and n 
 8 for L-Cys). ***, p 	 0.0001; **, p 	 0.005. E, time series plot as in A–C, except that the cells were
exposed to 1 mM L-NAME together with 1 mM DTT before exposure to 3 M CORM-2. F, bar graph showing mean  S.E. inhibition of peak Na current (measured
as in A–C) caused by 3 M CORM-2 applied alone (solid bar) of after treatment with 1 mM L-NAME alone (from Fig. 4) or together with DTT (n 
 10 cells). ***, p 	
0.0001.
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ments was 100 mV, and at this potential changes in steady-
state inactivation properties caused by CO can only account for
10% of the CO-mediated inhibition. This inhibition of peak
Na current is clinically important because reductions of peak
Na current amplitude (arising primarily from mutations in
Nav1.5) account for a large fraction of arrhythmias seen in Bru-
gada syndrome patients, regardless of whether amplitude
reduction arises from disrupted channel trafficking or function
(25, 49).
Through studying the effects of CO on recombinant Nav1.5
expressed inHEK293 cells, we can clearly distinguish the ability
of CO to inhibit the peak Na current from its ability to
increase the late component of the native Na current. Thus,
CO retained the ability to inhibit the peak current, yet the late
current was unaffected by CO (Figs. 1 and 2). This lack of effect
on the late current was not due to an inability of the channel to
display such activity because rATX-II caused a dramatic gating
shift and the appearance of a late current. However, this was
inhibited along with the peak current by CO (Fig. 2). Although
the lack of late current induction by COdistinguishes its effects
on the late from the peak current, it is noteworthy that both late
current induction (24) and inhibition of peak current were
largely mediated by formation of NO. Thus, in cardiomyocytes
(24), HEK293 cells (Fig. 4), and other cell types (48), CO
increased intracellularNO levels, and in each case, the effects of
CO were prevented or dramatically reduced by inhibiting NO
formation. However, it is equally noteworthy that although the
augmentation of the late current by CO could be mimicked by
an NO donor (24), the inhibition of the peak current could not
(Fig. 5). This observation further distinguishes themechanisms
underlying the effects of CO on peak and late cardiac Na cur-
rents and agrees with an earlier report of a lack of effect of NO
donors on expressed cardiac Na channels (50).
A previous study has indicated that cardiac Na channels
exist in a protein complex that also includes nNOS and that
constitutive activity of nNOS (arising from a mutation of the
scaffolding protein syntrophin, also present in the complex)
leads to channel nitrosylation and induction of the late Na
current (38). When we co-expressed cells with nNOS (Fig. 6),
CO was indeed able to increase the late Na current. This
experiment demonstrated that recombinant Nav1.5 channel 
subunits could generate a late Na current in the absence of
auxiliary subunits and that this effect was dependent on nNOS
co-expression. Whether this was due simply to increased NO
production or through specific colocalization of nNOS with
Nav1.5, we do not know. However, most importantly, it further
supported our conclusion that inhibition of the peak Na cur-
rent, despite also beingNO-dependent, occurred via a different
pathway/mechanism to the induction of the late Na current.
Systematic pharmacological analysis discounted the involve-
ment of ROS (from mitochondria and other sources), the
cGMP/PKG pathway, and both CAMK II and p38MAPK (Fig.
3), all of which have been implicated in the diverse effects of
CO, NO, or both gasotransmitters in other systems. Experi-
ments reported in Fig. 6 indicate that the redox status of cys-
teine residueswithinNav1.5 influence the channel sensitivity to
CO. In line with a previous report in guinea pig myocytes (51),
DTT was without significant effect itself on recombinant
Nav1.5 at 1 mM (Fig. 7A). However, others have reported a
modest augmenting effect of DTT on the cardiac Na channel
(39) and a larger effect at higher concentrations in Nav1.5
derived from human jejunum smooth muscle (41). The most
striking effect of DTT we found was to dramatically reduce the
effect of subsequent exposure to CO, suggesting that CO sen-
sitivity requires that key residues within the channel protein
must be in an oxidized state. Yatsuhashi et al. (40) have
reported that recombinant human cardiac Na channels
expressed in COS7 cells are modestly inhibited by L-cysteine at
the concentration reported here (100 M; Fig. 7C). We did not
detect such an effect, yet L-cysteine was not without influence
since it significantly reduced the channel sensitivity to CO, as
did the alkylating agent N-ethylmaleimide (Fig. 7B). Overall,
these findings indicate that the redox state of key channel cys-
teine residues strongly influences the ability of CO to inhibit
peak Na channel amplitude.
In summary, we have demonstrated that CO is a potentmod-
ulator of cardiac Na channels and that its ability to inhibit the
peak Na current is mechanistically distinct from its ability to
induce late Na currents. Although both effects involve forma-
tion of NO and are likely to be proarrhythmic, inhibition of
peak Na currents cannot be mimicked by NO donors, do not
appear to involve recognized signaling pathways, and are in part
dependent on the redox status of the channel. Such actions of
CO must be taken into consideration when evaluating this
important gasotransmitter as a therapeutic agent.
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